Although nonalcoholic fatty liver disease (NAFLD) Decreased Survival of Subjects with Elevated Liver Function Tests During a 28-Year Follow-Up
|
|
- Franklin Turner
- 5 years ago
- Views:
Transcription
1 Decreased Survival of Subjects with Elevated Liver Function Tests During a 28-Year Follow-Up Cecilia Söderberg, 1 Per Stål, 2,3 Johan Askling, 1 Hans Glaumann, 3 Greger Lindberg, 3 Joel Marmur, 3 and Rolf Hultcrantz 2,3 The long-term survival of subjects with nonalcoholic fatty liver disease (NAFLD) in comparison with both individuals with elevated transaminases attributable to other causes and the general poulation is poorly characterized. This study was undertaken to determine the frequency of NAFLD in a cohort of subjects who underwent liver biopsy from 1980 to 1984 because of elevated liver enzymes, and to assess mortality among subjects with NAFLD in comparison with the general Swedish population. The 256 subjects (61% men) had a mean age of years at the inclusion. Liver biopsies were blindly scored for NAFLD and nonalcoholic steatohepatitis (NASH). Causes of death were ascertained from the national Swedish Cause of Death Registry. Fatty liver was detected in 143 of the 256 subjects, including 25 (10%) with alcoholic fatty liver disease and 118 (46%) exhibiting NAFLD. Of those, 51 (20%) were classified as NASH and 67 (26%) as nonalcoholic bland steatosis. Cirrhosis was present in 9% at inclusion. During the follow-up period, 113 (44%) of the total population and 47 (40%) of the 118 subjects diagnosed with NAFLD died. Of the 113 deaths, 37 were of cardiovascular disease and 16 of liver diseases. Compared with the total Swedish population, adjusted for sex, age, and calendar period, subjects with NAFLD exhibited a 69% increased mortality (standardized mortality ratio [SMR] 1.69; 95% confidence interval [CI], ); subjects with bland steatosis, a 55% increase (SMR, 1.55; 95% CI, ; P 0.062); and subjects with NASH, 86% (SMR, 1.86; 95% CI, ; P 0.007). Conclusion: Patients with NASH are at increased risk of death compared with the general population. Liver disease is the third most common cause of death among patients with NAFLD. (HEPATOLOGY 2010;51: ) See Editorial on Page 373 Although nonalcoholic fatty liver disease (NAFLD) is the most common cause of elevated serum levels of liver enzymes in the Western world, the longterm outcome of this condition is poorly characterized. In Abbreviations: AFLD, alcoholic fatty liver disease; ALT, alanine aminotransferase; CI, confidence interval; HCC, hepatocellular carcinoma; NAFLD, nonalcoholic fatty liver disease; NASH, nonalcoholic steatohepatitis; SMR, standardized mortality ratio. From the 1 Department of Medicine, Karolinska Institute, Solna, Stockholm, Sweden; the 2 Department of Gastroenterology and Hepatology, Karolinska University Hospital, Stockholm, Sweden; and the 3 Department of Medicine, Karolinska Institute, Huddinge, Stockholm, Sweden. Received December 5, 2008; accepted September 3, Supported by Swedish Research Council (grant no. 9127); Bengt Ihre Foundation; and by funds from the Karolinska Institutet. Address reprint requests to: Cecilia Söderberg, MSc, Unit of Gastroenterology and Hepatology, Karolinska University Hospital, Stockholm, Sweden. cecilia.soderberg@ki.se; fax: (46) Copyright 2009 by the American Association for the Study of Liver Diseases. Published online in Wiley InterScience ( DOI /hep Potential conflict of interest: Nothing to report. the early 1980s, increased determination of aminotransferase levels in connection with health surveys and screening programs led to improved detection of individuals with pathological liver function. Among adults, the most common abnormalities observed in the absence of symptoms are an elevated level of alanine aminotransferase (ALT) or gamma-glutamyltransferase activity. ALT levels are elevated in 2.8% of the general population, 1 and in approximately 10% of these cases, no cause for this chronic hypertransaminasemia can be identified. The prognosis in connection with this condition remains unknown. 2,3 In two studies performed in the early 1980s, we found that 56% of asymptomatic subjects with elevated serum levels of hepatic enzymes who had undergone liver biopsy had fatty liver. 4,5 Nonalcoholic steatohepatitis (NASH) had not been characterized as an important entity at that time. 6,7 Recent evidence shows that some individuals with NAFLD have or develop NASH, which may lead to cirrhosis and an elevated risk for hepatocellular carcinoma (HCC)
2 596 SÖDERBERG ET AL. HEPATOLOGY, February 2010 Table 1. Clinical and Biochemical Features of the 256 Swedish Individuals Referred for Appraisal Because of Asymptomatic Elevation of Serum Levels of Alanine Aminotransferase Diagnosis Based on Biopsy N (Total 256) Patients with Cirrhosis (Total 23) Men/Women ALP (nv < 4.6) AST (nv > 0.7) ALT (nv > 0.7) Bland steatosis / NASH / ASH/AFLD / ALD / AIH / Normal / Hep C / Hep B 7 3 7/ Hep C B 4 1 2/ HH 3 1 2/ AAT-deficiency 6 0 4/ Other / Abbreviations: ALP, alkaline phosphatase; AST, aspartate aminotransferase; ALT, alanine aminotransferase; Nv, normal value. The values for ALP, AST, and ALT are in kat/l. The long-term prognosis for individuals with NAFLD and NASH has been investigated in population-based studies 9,10 as well as in a cohort study in which NAFLD was considerd by biopsy, 11 with a longest follow-up period so far of 14 years. Although the overall survival in connection with NAFLD was found to be slightly decreased, 9 this reduction has been attributed to enhanced mortality, specifically among the subpopulation suffering from NASH, 11 in which case bland steatosis might not alter the risk of death. The longer-term survival for subjects with NAFLD (with and without steatohepatitis) in comparison with both those with elevated serum levels of transaminases from other causes and the general poulation is thus incompletely characterized. The aim of the current investigation was to examine the mortality and causes of death in a cohort of subjects with elevated serum levels of aminotransaminases. Furthermore, we wanted to determine the frequency of NAFLD and NASH in this population and compare the survival and causes of death in NAFLD subjects of those subjects with other liver diseases, and of the general population. Patients and Methods Subjects. Between 1980 and 1984, 232 subjects with unexplained elevated serum levels of ALT, and therefore referred to our unit, have been characterized in a retrospective (n 149) and a prospective (n 83) study by Hultcrantz and coworkers. 4,5 Twenty-four additional subjects excluded from this previous prospective study because of a lack of radiological data were also included in the current follow-up study, giving 256 subjects altogether. The inclusion criteria were persistently elevated levels of aspartate aminotransferase and alanine aminotransferase (ALT) for longer than 6 months. Subjects with symptoms or clinical signs of liver disease were excluded, as were those with serum levels of alkaline phosphate (greater than twice the upper normal limit, that is, 4.2 kat/l) and those exhibiting clinical or laboratory signs of kidney disease. The mean age at the time of liver biopsy was 48.5 years for the men and 48.3 years for the women in the retrospective study, and the corresponding ages in the prospective study were 41 and 42 years, respectively (Table 1). Unless otherwise stated in the medical chart by the two physicians (and co-authors R.H. and G.L.), the patient was assumed not to overconsume alcohol. A great deal of effort was put into uncovering any such overconsumption at the time. As noted in the medical records, testing for hepatitis C virus had been performed on 70 of our subjects, and 37 were positive. Of the 25 subjects with NAFLD who were tested, all were negative. Of the 47 in the latter group, 16 died before 1991, when such testing became generally available in Sweden. Of these 47 deceased subjects with NAFLD, two had been tested and were found to be negative for hepatitis C virus. No one in this group had any medical history of intravenous drug abuse or blood transfusions; nor did any exhibit the liver inflammation with portal infiltrates indicative of hepatitis C virus infection. Follow-up and Identification as Still Living or Deceased. All Swedish residents are assigned a unique 10- digit national registration number, and these identification numbers are recorded in the nationwide and virtually complete Cause of Death Registry. 12 Through this registry, information concerning all deaths
3 HEPATOLOGY, Vol. 51, No. 2, 2010 SÖDERBERG ET AL. 597 Fig. 1. Reevaluation, scoring, and classification of the 256 original liver biopsies. Diagnoses were made on the basis of scoring and the subjects medical records. The white bars depict the total number of subjects in each group and the black bars the number of deceased subjects (113 in all). during the study period (1980 to July 9, 2008), including dates and causes of death (coded according to the International Classifications of Diseases versions 8, 9, and ) could be obtained. Similarly, through the national and continuously updated Population Registry, individuals still alive and residing in Sweden could be identified, so that the follow-up was complete. Reevaluation of the Initial Liver Biopsies. On an outpatient basis, liver biopsies had been performed on all of the subjects percutaneously with a 1.6-mm Menghinitype needle. All of these biopsies were reevaluated employing a modern classification by two of the authors (C.S. and R.H.), as well as by a third reference person (H.G.), all of whom were blinded to the patient details. Liver histology was scored in accordance with the system developed by Kleiner and Brunt et al. 16 A classification of NASH was made on the basis of steatosis, lobular inflammation, and ballooning degeneration, and fibrosis was scored to determine the stage (progression) of this condition. For grading disease activity in connection with chronic hepatitis, we used the scoring system developed by Batts and Ludwig. 17 Iron content was evaluated according to Scheuer 18 as no, weak, moderate, or intense staining, and localization predominantly in Kupffer cells or in hepatocytes. Statistical Analysis. To assess the relative risk of death, we employed standardized mortality ratios (SMR), that is, the ratio between the observed numbers of deaths in the cohort compared with the number expected on the basis of mortality rates for the general population. The expected numbers of deaths were calculated by adding all person-years accumulated in the cohort into strata (sex, age [in 5-year groups) and calendar year of follow-up [in 5-year intervals]) and then multiplying the stratum-specific person-years by the corresponding stratum-specific incidence rates for the entire Swedish population. Ninetyfive percent confidence intervals (CI) were calculated assuming that the observed events followed a Poisson distribution. Follow-up began at the date of the initial liver biopsy and ended on July 9, 2008, or, if earlier, the date of death. Kaplan-Meier curves are used to depict the mortality in the cohort graphically. All analyses were conducted using SAS statistical software. This study was approved by the regional ethics committee at the Karolinska Institutet in Stockholm. Results Reevaluation of the Liver Biopsies. Figure 1 depicts the distribution of diagnoses obtained by reevaluation of the liver biopsy specimens from our 256 subjects. Fatty deposition of greater than 5% was detected in the livers of 143 subjects (56%). According to the medical records, 25 of these 143 abused alcohol, and their condition was therefore classified as alcoholic fatty liver disease (AFLD). The remaining 118 had NAFLD, including 51 cases of NASH, and 67 of bland steatosis.
4 598 SÖDERBERG ET AL. HEPATOLOGY, February 2010 Of the 256 subjects, 41 (16%) exhibited chronic viral hepatitis, and of these 30 had hepatitis C alone and seven hepatitis B alone, the remaining four subjects being coinfected with both of these viruses. In addition to the 25 subjects with AFLD (see earlier discussion), 10 others (4%) among the 256 subjects had a history of alcohol abuse; however, the biopsy specimens of these 10 contained less than 5% fat, so they were classified as suffering from alcoholic liver disease without steatosis. Eleven subjects (4%) demonstrated autoimmune hepatitis; three (1%), hemochromatosis; six (2%), a deficiency in alpha 1 - antitrypsin; 13 (5%), unspecific histopathological findings; and 29 (11%), no apparent abnormality at all. At the time of biopsy, cirrhosis was present in 23 of the 256 subjects (9%) (including five with NASH, four with bland steatosis, and two with alcoholic steatohepatitis/ AFLD, three with alcoholic liver disease, seven with viral hepatitis, one with hemochromatosis, and one other). Relative Risk of Death. We followed-up our 256 subjects for a total of 5,248 person-years (median period of follow-up, 24 years [range, years]; mean period of follow-up, 21 years [standard deviation, 7.7]). The subjects with fatty liver were slightly overweight, with a body mass index of for those with bland steatosis and for those with NASH. The corresponding mean ages at the time of biopsy were and 49.4 years, respectively. The prognoses of the 256 subjects who underwent liver biopsy and the 118 subjects with NAFLD are given in Fig 2A-C and Tables 2 and 3. During this follow-up, 113 subjects died, which corresponded to an 80% increased risk of death in comparison with the general population (SMR, 1.8; 95% CI, ; Table 3). Of the 118 subjects with NAFLD, 47 died (SMR, 1.7; 95% CI ); among the 67 with bland steatosis, 23 died (SMR, 1.6; 95% CI, ; P 0.062); among the 51 with NASH, 24 died (SMR, 1.9; 95% CI, ; P 0.007) (Table 3, Fig. 2A). When the nine patients with cirrhosis among those with bland steatosis or NASH were omitted from the calculation, the relative risks of death for those two groups were 1.3 (95% CI, ) and 1.7 (95% CI, ), respectively (Table 3). When subjects with stage 3 fibrosis were also omitted from these same two groups, the corresponding values were 1.1 (95% CI, ) and 1.7 (95% CI, ), respectively (Table 3). Furthermore, of the eight subjects with fatty liver but no inflammation, fibrosis, or ballooning at all, one was deceased (Fig. 2B). When the subjects were grouped for analysis according to their NASH Activity Score (0-2 [SMR, 1.01; 95% CI, ], 3-4 [SMR, 2.05; 95% CI, ], and 5-8 [SMR, 1.82; 95% CI, ]), subjects in NASH Activity Score classes 3 to 4 and 5 to 8 had an increased risk of death (Table 2). In the case of the AFLD/ASH subjects, a 294% increased risk of death was observed (SMR, 3.9; 95% CI, ). Chronic infection with hepatitis C or B was associated with an increased risk of death (Table 3; Fig. 2C). By contrast, subjects with autoimmune hepatitis or another diagnosis did not exhibit reduced survival, although certain subsets contained too few subjects to allow valid comparison (Table 3). Of the 23 subjects with cirrhosis, 18 died during our follow-up. Causes of Death. Of the 67 deaths among our subjects with fatty liver (AFLD NAFLD), 22 (33%) were attributable to cardiovascular disease, 14 (21%) to extrahepatic malignancy, and 16 (24%) to liver diseases, including HCC. Among those with NAFLD, 14 (30%) died of cardiovascular disease, 13 (28%) of extrahepatic malignancies, and nine (19%) of liver disease. Eight AFLD subjects (40%) died of cardiovascular disease, and seven (35%) died of liver disease, whereas the subjects with alcoholic liver disease died primarily of malignancies (three subjects, 38%) (Table 4). Subjects with liver cirrhosis died of their cirrhosis (n 5), extrahepatic malignancies (n 4), liver cancer (n 3), cardiovascular disease (n 3), external causes (n 1), and alcohol (n 1). The stages of fibrosis of those in the NAFLD group who died are documented in Table 5. Discussion The current report documents the longest follow-up of patients who originally demonstrated elevated serum levels of hepatic enzymes and were subsequently shown by biopsy to be suffering from NAFLD. This study has four major strengths: First, all of the subjects were enrolled consecutively during a defined period ( ). Second, all underwent liver biopsy at the time of referral, so that the diagnoses of NAFLD are based on histological criteria. Third, reevaluation of the initial biopsy findings was performed in all cases. And finally, even deceased subjects could be followed-up through the Cause of Death Registry, so that there were no losses during follow-up. The scoring system developed by Kleiner et al. 16 combines the three parameters hepatic fat content, lobular inflammation, and ballooning, all of which contribute equally to the NASH score. Thus, a patient with pronounced steatosis and relatively moderate inflammation could receive the same NASH score as one with mild steatosis but intense inflammation and ballooning. One disadvantage to this scoring system is that it does not take fibrosis into consideration. Among our subjects with bland steatosis, we found eight with severe fibrosis or
5 HEPATOLOGY, Vol. 51, No. 2, 2010 SÖDERBERG ET AL. 599 Fig. 2. Overall survival of subjects in the study with NASH or bland steatosis and the entire cohort. (A) Overall survival subjects with NASH or bland steatosis.and the entire cohort of 256. Of the 118 subjects with NAFLD, 47 died. Twenty-three patients of the 67 with bland steatosis died (SMR, 1.6; 95% CI, ; P 0.062); among the 51 with NASH, 24 died (SMR, 1.9; 95% CI, ; P 0.007). (B) Overall survival of subjects with NAFLD, divided into those with only fatty liver or subjects with fat and any type of inflammation, ballooning, or fibrosis. (C) Overall survival among subjects with NAFLD compared with those with alcoholic fatty liver and hepatitis C.
6 600 SÖDERBERG ET AL. HEPATOLOGY, February 2010 Table 2. The Stage of Fibrosis in the Subjects with NAFLD Stage of Fibrosis NAS-Score Missing No-NASH (1-2) Alive (24) Dead (8) Border line (3-4) Alive (18) Dead (15) NASH (5-8) Alive (29) Dead (24) Table 3. Standardized Mortality Ratios (SMR) for Subjects with Elevated Serum Levels of Alanine Aminotransferase in Comparison with the General Swedish Population (Adjusted for Sex, Age, and Calendar Period) Number of Deceased RR CI 95% Approximate P Value (2-Tailed) Whole sample * Bland steatosis NASH * ASH/AFLD * ALD * Hep C * Hep B * Hep C B * AIH HH AAT-deficiency Other Normal Excluding cirrhosis Bland steatosis , NASH * Excluding cirrhosis and fibrosis stage 3 0 Bland steatosis NASH * Subjects grouped on the basis of their final diagnose. In the case of NAFLD SMRs were also calculated with the omission of severe fibrotic or patients with cirrhosis. Table 4. Causes of Death for All Deceased Subjects (Obtained from the Swedish Causes of Death Registry) Diagnosis Cause of Death Bland Steatosis (23) NASH (24) ASH/AFLD (20) Alcohol (8) Hep C (13) Hep B (4) Hep C & Hep B (2) AIH (5) AAT-defic (0) HH (1) Other (7) Normal (6) Cardiovascular disease Extrahepatic malignancy Cirrhosis Liver cancer Alcohol Respiratory disease Diabetes Poisoning/accident Bleeding from duodenum 1 Chronical pancreatitis 1 0 Other/unknown In subjects with NAFLD, the main cause of death was cardiovascular disease, followed by extrahepatic malignancies and, next, liver-related causes, including HCC.
7 HEPATOLOGY, Vol. 51, No. 2, 2010 SÖDERBERG ET AL. 601 Table 5. The Cause of Death in the Deceased Patients with NAFLD Cause of Death Stage of Fibrosis Missing Cirrhosis Perforation of intestine 1 Liver cancer Extrahepatic cancer Diabetes 2 1 Cardiovascular Alcohol abuse 1 Poisoning/accident The number of patients with fibrosis stage 0 4 is given for each group of patients with a specific cause of death. cirrhosis, which is unexpected in the absence of NASH. As a consequence, to evaluate the prognostic value of fatty liver without significant fibrosis, we also performed analyses omitting these eight subjects. Subjects with bland steatosis without severe fibrosis or cirrhosis at the time of biopsy exhibited no increased risk of death. When patients with cirrhosis or severe fibrosis are excluded from the group with bland steatosis, deaths attributable to either cirrhosis or liver cancer are much less common. Both for subjects with fatty liver and for the whole study population, we found that persistently elevated serum levels of liver enzymes were associated with an increased risk of death during the study period. As a group, subjects with NAFLD demonstrated a significantly increased risk of death, but this risk was not as high as for patients with chronic viral hepatitis or alcoholic liver disease (Fig. 2C). In our population, those with NAFLD exhibited poorer survival than those with autoimmune hepatitis, hemochromatosis, or alpha-1-antitrypsin deficiency taken combined. It is currently unknown why certain patients diagnosed by biopsy as suffering from NAFLD and elevated serum levels of liver enzymes develop inflammation and fibrosis (NASH). One of the main findings presented here is that survival among these subjects is lower than among the matched reference population. Recently, Adams and coworkers 9,11,19 also reported that survival among NAFLD subjects is lower than expected in comparison with the general population. In most cases, their diagnosis of NAFLD was based on imaging rather than histological examination. Moreover, in a 14-year follow-up, Ekstedt et al. 11 demonstrated that survival of patients with NASH was lower than expected in comparison with the general population. In the current 28-year follow-up, we have confirmed these findings. The main causes of death among our subjects with NASH were cardiovascular disease, followed by extrahepatic cancers and next hepatic diseases. As expected, cardiovascular diseases were found to be the major cause of death in the current investigation. Recent epidemiological studies indicate an increased incidence of major cardiovascular events in subjects with NAFLD, independent of traditional risk factors and aspects of the metabolic syndrome A higher risk for cardiovascular mortality compared with the reference population has been shown in subjects shown to have NAFLD though biopsy 11 as well as in a population-based cohort study. 22 Liver diseases, including hepatocellular carcinoma (HCC), were found to be the third largest cause of death among subjects with NAFLD. HCC is a major health problem worldwide, with more than 500,000 cases diagnosed annually. 23 Whereas the incidence of HCC has been increasing during the last 5 to 8 years, the survival of those affected has not changed significantly during the past two decades. With NAFLD becoming more and more common, with enhanced prevalence among younger people, the associated rise in relative risk of mortality and terminal liver disease will be of considerable significance to public health in the future. In the current investigation, four subjects with NAFLD/NASH died of complications of cirrhosis, and five died of HCC. It thus seems reasonable to recommend changes in lifestyle for all subjects with NAFLD. It has been shown previously that examination of a liver biopsy at entry into the healthcare system is a valuable predictor of future cirrhosis-related complications, exhibiting a positive predictive value of 18% in subjects with periportal fibrosis and a negative predictive value of 100% for those without established periportal fibrosis. One of four (25%) patients with cirrhosis at baseline, 3 of 12 patients (25%) with stage 3 fibrosis at baseline, and three patients of 22 (14%) with stage 2 fibrosis at baseline were found to have developed end-stage liver disease during follow-up. 11 Of the nine subjects diagnosed with NAFLD and concomitant cirrhosis at the time of inclusion in the current study, three died of liver cancer, two of extrahepatic cancers, one of cirrhosis, one of cardiovascular disease, and one in an accident. Only one remains alive. We conclude that in our cohort of subjects with elevated serum levels of liver enzymes who underwent consecutive liver biopsies 28 years ago, 46% could be diagnosed as suffering from NAFLD. At the time of the initial biopsy, 8% of those with NAFLD had cirrhosis, and 43% had NASH. Overall survival was reduced in subjects with NAFLD and NASH, whereas bland steato-
8 602 SÖDERBERG ET AL. HEPATOLOGY, February 2010 sis with or without severe fibrosis was not associated with any increase in mortality risk in comparison with the general population. Patients with NASH had a lower risk of death than those with alcoholic liver disease or chronic viral hepatitis but a higher risk than those suffering from autoimmune and metabolic liver diseases. On the whole, patients with NAFLD die of liver-related causes to a greater extent than the general population, but we still see cardiovascular disease and extrahepatic malignancies to be the primary and secondary causes of deaths among these patients. The frequency of HCC is almost 1000-fold higher in this group than what has been reported for Sweden earlier. Our findings motivate a more active approach to the diagnosis and treatment of NASH, with more frequent use of liver biopsy for diagnosis. Thus, subjects with NASH have an increased risk of death; much emphasis should be put into treatment. New treatment strategies have to be sought. References 1. Ludwig J, Viggiano TR, McGill DB, Oh BJ. Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease. Mayo Clin Proc 1980;55: Kundrotas LW, Clement DJ. Serum alanine aminotransferase (ALT) elevation in asymptomatic US Air Force basic trainee blood donors. Dig Dis Sci 1993;38: Pratt DS, Kaplan MM. Evaluation of abnormal liver-enzyme results in asymptomatic patients. N Engl J Med 2000;342: Hultcrantz R, Glaumann H, Lindberg G, Nilsson LH. Liver investigation in 149 asymptomatic patients with moderately elevated activities of serum aminotransferases. Scand J Gastroenterol 1986;21: Hultcrantz R, Gabrielsson N. Patients with persistent elevation of aminotransferases: investigation with ultrasonography, radionuclide imaging and liver biopsy. J Intern Med 1993;233: Brunt EM, Janney CG, Di Bisceglie AM, Neuschwander-Tetri BA, Bacon BR. Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions. Am J Gastroenterol 1999;94: Bacon BR, Farahvash MJ, Janney CG, Neuschwander-Tetri BA. Nonalcoholic steatohepatitis: an expanded clinical entity. Gastroenterology 1994;107: Bugianesi E, Leone N, Vanni E, Marchesini G, Brunello F, Carucci P, Musso A, et al. Expanding the natural history of nonalcoholic steatohepatitis: from cryptogenic cirrhosis to hepatocellular carcinoma. Gastroenterology 2002;123: Adams LA, Lymp JF, St Sauver J, Sanderson SO, Lindor KD, Feldstein A, et al. The natural history of nonalcoholic fatty liver disease: a populationbased cohort study. Gastroenterology 2005;129: Ong JP, Pitts A, Younossi ZM. Increased overall mortality and liver-related mortality in non-alcoholic fatty liver disease. J Hepatol 2008;49: Ekstedt M, Franzen LE, Mathiesen UL, Thorelius L, Holmqvist M, Bodemar G, et al. Long-term follow-up of patients with NAFLD and elevated liver enzymes. HEPATOLOGY 2006;44: Causes of death register. Accessed October World Health Organization. International Classification of Diseases World Health Organization. International Classification of Diseases World Health Organization. International Classification of Diseases Kleiner DE, Brunt EM, Van Natta M, Behling C, Contos MJ, Cummings OW, et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. HEPATOLOGY 2005;41: Batts KP, Ludwig J. Chronic hepatitis: an update on terminology and reporting. Am J Surg Pathol 1995;19: Lefkowitch PJSaR. In: Liver biopsy interpretation, Eur J Hepatol Gastroenterol 1991: Hamaguchi M, Kojima T, Takeda N, Nagata C, Takeda J, Sarui H, et al. Nonalcoholic fatty liver disease is a novel predictor of cardiovascular disease. World J Gastroenterol 2007;13: Targher G, Bertolini L, Poli F, Rodella S, Scala L, Tessari R, et al. Nonalcoholic fatty liver disease and risk of future cardiovascular events among type 2 diabetic patients. Diabetes 2005;54: Targher G, Bertolini L, Rodella S, Tessari R, Zenari L, Lippi G, et al. Nonalcoholic fatty liver disease is independently associated with an increased incidence of cardiovascular events in type 2 diabetic patients. Diabetes Care 2007;30: Dunn W, Xu R, Wingard DL, Rogers C, Angulo P, Younossi ZM, et al. Suspected nonalcoholic fatty liver disease and mortality risk in a population-based cohort study. Am J Gastroenterol 2008;103: Parkin DM, Bray F, Ferlay J, Pisani P. Estimating the world cancer burden: Globocan Int J Cancer 2001;94:
SAF score and mortality in NAFLD after up to 41 years of follow-up
SAF score and mortality in NAFLD after up to 41 years of follow-up Hannes Hagström, Patrik Nasr, Mattias Ekstedt, Stergios Kechagias, Per Stal, Pierre Bedossa and Rolf Hultcrantz Journal Article N.B.:
More informationChallenges in the Diagnosis of Steatohepatitis
The Bugaboos of Fatty Liver Disease: Ballooning and Fibrosis Hans Popper Hepatopathology Society Companion Meeting San Antonio, Tx March, 2017 David Kleiner, M.D., Ph.D. NCI/Laboratory of Pathology Challenges
More informationCDHNF & NASPGHAN A Partnership for Research and Education for Children s Digestive and Nutritional Health
CDHNF & NASPGHAN A Partnership for Research and Education for Children s Digestive and Nutritional Health Obesity and NAFLD Definitions: Nonalcoholic steatohepatitis (NASH) and nonalcoholic fatty liver
More informationLiver Pathology in the 0bese
Liver Pathology in the 0bese Rob Goldin Centre for Pathology, Imperial College r.goldin@imperial.ac.uk Ludwig et al. Non-alcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease.
More informationCase #1. Digital Slides 11/6/ year old woman presented with abnormal liver function tests. Liver Biopsy to r/o autoimmune hepatitis
45 year old woman presented with abnormal liver function tests Liver Biopsy to r/o autoimmune hepatitis Further down. ANA 1: 160; ASMA 1:80 ANA 1: 160; ASMA 1:80 IgG = 14.5 g/l (upper normal range: 16)
More informationNonalcoholic Fatty Liver Disease: Definitions, Risk Factors, and Workup
REVIEW REVIEW Nonalcoholic Fatty Liver Disease: Definitions, Risk Factors, and Workup Puneet Puri, M.B.B.S., M.D. and Arun J. Sanyal, M.B.B.S., M.D. Nonalcoholic fatty liver disease (NAFLD) is defined
More informationOriginal Article. Significance of Hepatic Steatosis in Chronic Hepatitis B Infection INTRODUCTION
Original Article Bhanthumkomol P, et al. THAI J GASTROENTEROL 2013 Vol. 14 No. 1 Jan. - Apr. 2013 29 Bhanthumkomol P 1 Charatcharoenwitthaya P 1 Pongpaiboon A 2 ABSTRACT Background: Significance of liver
More informationUpdate on Non-Alcoholic Fatty Liver Disease. Timothy R. Morgan, MD Chief, Hepatology, VA Long Beach Professor of Medicine, UCI
Update on Non-Alcoholic Fatty Liver Disease Timothy R. Morgan, MD Chief, Hepatology, VA Long Beach Professor of Medicine, UCI February 3, 2018 Disclosure Clinical trials: Genfit Speaker s Bureau: none
More informationNAFLD & NASH: Russian perspective
NAFLD & NASH: Russian perspective Vasily Isakov, MD, PhD Professor, Chief, Department Gastroenterology & Hepatology, Federal Research Center of nutrition, biotechnology and food safety Disclosures Received
More informationNonalcoholic fatty liver disease (NAFLD) is the most common
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY 2008;6:1249 1254 Cytokeratin 18 Fragment Levels as a Noninvasive Biomarker for Nonalcoholic Steatohepatitis in Bariatric Surgery Patients DIMA L. DIAB,* LISA YERIAN,
More informationLiver biopsy as the gold standard for diagnosis. Pierre BEDOSSA
Liver biopsy as the gold standard for diagnosis Pierre BEDOSSA 1 PATHOLOGY OF NAFLD CONFLICTS OF INTEREST Grants and funding from Genfit, Intercept, Allergan, Inventiva, OWL, Echosens CEO and funding of
More informationNON-ALCOHOLIC STEATOHEPATITIS AND NON-ALCOHOLIC FATTY LIVER DISEASES
NON-ALCOHOLIC STEATOHEPATITIS AND NON-ALCOHOLIC FATTY LIVER DISEASES Preface Zobair M. Younossi xiii Epidemiology and Natural History of NAFLD and NASH 1 Janus P. Ong and Zobair M. Younossi Understanding
More informationPatients With NASH and Cryptogenic Cirrhosis Are Less Likely Than Those With Hepatitis C to Receive Liver Transplants
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY 2011;9:700 704 Patients With NASH and Cryptogenic Cirrhosis Are Less Likely Than Those With Hepatitis C to Receive Liver Transplants JACQUELINE G. O LEARY, CARMEN
More informationA Modification of the Brunt System for Scoring Liver Histology of Patients with Non-Alcoholic Fatty Liver Disease
Arch Iran Med 2010; 13 (1): 38 44 Original Article A Modification of the Brunt System for Scoring Liver Histology of Patients with Non-Alcoholic Fatty Liver Disease Shahin Merat MD*, Farzaneh Khadem-Sameni
More informationLong term follow-up and liver-related death rate in patients with non-alcoholic and alcoholic related fatty liver disease
Haflidadottir et al. BMC Gastroenterology 2014, 14:166 RESEARCH ARTICLE Open Access Long term follow-up and liver-related death rate in patients with non-alcoholic and alcoholic related fatty liver disease
More informationPrognosis of NASH VII Workshop Intenracional de Actualizaçao em Hepatologia, Aug 29th 2014
Prognosis of NASH VII Workshop Intenracional de Actualizaçao em Hepatologia, Aug 29th 2014 Vlad Ratziu, Université Pierre et Marie Curie, Hôpital Pitié Salpêtrière, Paris, France NASH : a severe hepatic
More informationThe role of non-invasivemethods in evaluating liver fibrosis of patients with non-alcoholic steatohepatitis
The role of non-invasivemethods in evaluating liver fibrosis of patients with non-alcoholic steatohepatitis Objectives: Liver biopsy is the gold standard for diagnosing the extent of fibrosis in NAFLD/NASH;
More informationNONALCOHOLIC FATTY LIVER DISEASE. Non-Alcoholic Fatty Liver Disease (NAFLD) Primary NAFLD. April 13, 2012
NONALCOHOLIC FATTY LIVER DISEASE Kiran Bambha, MD University of Colorado Denver April 13, 2012 Non-Alcoholic Fatty Liver Disease (NAFLD) Primary NAFLD Simple Steatosis Fatty hepatocytes Intracellular fat
More informationAAIM: GI Workshop Follow Up to Case Studies. Non-alcoholic Fatty Liver Disease Ulcerative Colitis Crohn s Disease
AAIM: GI Workshop Follow Up to Case Studies Non-alcoholic Fatty Liver Disease Ulcerative Colitis Crohn s Disease Daniel Zimmerman, MD VP and Medical Director, RGA Global October 2015 Non-alcoholic Fatty
More informationFat, ballooning, plasma cells and a +ANA. Yikes! USCAP 2016 Evening Specialty Conference Cynthia Guy
Fat, ballooning, plasma cells and a +ANA. Yikes! USCAP 2016 Evening Specialty Conference Cynthia Guy Goals Share an interesting case Important because it highlights a common problem that we re likely to
More informationSteatotic liver disease
Steatotic liver disease Fatty liver disease Prof. Dr. ANNE HOORENS Non-Neoplastic Liver Pathology December 8th 2018 Working Group of Digestive Pathology Belgian Society of Pathology OUTLINE NAFLD = Non-Alcoholic
More informationLIVER, PANCREAS, AND BILIARY TRACT
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY 2012;10:1028 1033 LIVER, PANCREAS, AND BILIARY TRACT Prevalence and Indicators of Portal Hypertension in Patients With Nonalcoholic Fatty Liver Disease FLAVIA D.
More informationFatty liver disease in Sudan is not alcohol related Nail A M 1, Gadour MO 2, Khair MM 3, Salma BM 4, Suzan E 5
Fatty liver disease in Sudan is not alcohol related Nail A M 1, Gadour MO 2, Khair MM 3, Salma BM 4, Suzan E 5 Abstract: Background: The finding of fatty liver disease (FLD) has generally been assumed
More informationNon-Alcoholic Fatty Liver Diseasean underestimated epidemic
Non-Alcoholic Fatty Liver Diseasean underestimated epidemic Amir Shlomai MD,PhD Head, Department of Medicine D The Liver Institute Rabin Medical Center, Beilinson Hospital The IASLD semi-annual meeting-
More informationPHC, Paris, 30th Jan 2017 PATHOLOGY OF NAFLD. Pierre Bedossa. Departement of Pathology Hôpital Beaujon University Paris-Diderot Paris - FRANCE
PHC, Paris, 30th Jan 2017 PATHOLOGY OF NAFLD Pierre Bedossa Departement of Pathology Hôpital Beaujon University Paris-Diderot Paris - FRANCE 1 PATHOLOGY OF NAFLD NAFLD: a chronic liver disease with a wide
More informationALT and aspartate aminotransferase (AST) levels were measured using the α-ketoglutarate reaction (Roche,
Supplemental Methods Analytical determinations ALT and aspartate aminotransferase (AST) levels were measured using the α-ketoglutarate reaction (Roche, Basel, Switzerland). Glucose, triglyceride, total
More informationRole of Liver Biopsy. Role of Liver Biopsy 9/3/2009. Liver Biopsies in Viral Hepatitis: Beyond Grading and Staging
Liver Biopsies in Viral Hepatitis: Beyond Grading and Staging for further reference: Liver biopsy assessment in chronic viral hepatitis: a personal, practical approach Neil Theise, MD. Depts of Pathology
More informationLiver disease is a major cause of mortality and morbidity
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY 2011;9:524 530 Changes in the Prevalence of the Most Common Causes of Chronic Liver Diseases in the United States From 1988 to 2008 ZOBAIR M. YOUNOSSI,*, MARIA
More informationAmerican Journal of Oral Medicine and Radiology
American Journal of Oral Medicine and Radiology e - ISSN - XXXX-XXXX ISSN - 2394-7721 Journal homepage: www.mcmed.us/journal/ajomr PREVALENCE OF NONALCOHOLIC FATTY LIVER DISEASE AMONG TYPE 2 DIABETIC POPULATION
More informationLinda Ferrell, MD Distinguished Professor Vice Chair Director of Surgical Pathology Dept of Pathology
Linda Ferrell, MD Distinguished Professor Vice Chair Director of Surgical Pathology Dept of Pathology Nonalcoholic steatohepatitis and Fatty Liver Disease Liver manifestations of the obesity epidemic Changes
More informationFatty liver disease: What do we know?
Fatty liver disease: What do we know? Prof. Dr. Claus Niederau Katholische Kliniken Oberhausen ggmbh St. Josef-Hospital Academic Teaching Hospital University of Duisburg-Essen NAFLD Non-Alcoholic Fatty
More informationFirst European NAFLD-NASH Summit European Parliament, Brussels, May 31 st NAFLD/NASH : an expanding burden on liver health
First European NAFLD-NASH Summit European Parliament, Brussels, May 31 st 2017 NAFLD/NASH : an expanding burden on liver health Vlad Ratziu, Université Pierre et Marie Curie, Hôpital Pitié Salpêtrière,
More informationHepatocellular carcinoma is the most common liver-related complication in patients with histopathologically-confirmed NAFLD in Japan
Akuta et al. BMC Gastroenterology (2018) 18:165 https://doi.org/10.1186/s12876-018-0900-1 RESEARCH ARTICLE Open Access Hepatocellular carcinoma is the most common liver-related complication in patients
More informationDownloaded from zjrms.ir at 3: on Monday February 25th 2019 NAFLD BMI. Kg/m2 NAFLD
logistic regression Student s t-test P< BMI BMI P< ALT AST P< Email:mkhoshbaten@yahoo.com Kg/m2 NASH RUQ B C II Case-Control II Logistic Regression Chi-Square T-test P< Grade Model 1- A diffuse hyper echoic
More informationNON-ALCOHOLIC FATTY LIVER DISEASE:
NON-ALCOHOLIC FATTY LIVER DISEASE: ROLE OF THE PRIMARY PROVIDER Archita P. Desai, MD Assistant Professor of Medicine University of Arizona 25 th Annual Southwestern Conference on Medicine Outline Pathophysiology
More informationPEDIATRIC FOIE GRAS: NON-ALCOHOLIC FATTY LIVER DISEASE
PEDIATRIC FOIE GRAS: NON-ALCOHOLIC FATTY LIVER DISEASE Updates on New insights into NAFLD and NASH pathophysiology New AASLD/AGA/ACG guidelines for NAFLD and NASH, as pertains to pediatrics Evidence-based
More informationThe effect of aerobic exercise on serum level of liver enzymes and liver echogenicity in patients with non-alcoholic fatty liver disease
Gastroenterology and Hepatology From Bed to Bench. 2013 RIGLD, Research Institute for Gastroenterology and Liver Diseases ORIGINAL ARTICLE The effect of aerobic exercise on serum level of liver enzymes
More informationNON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD) NON-ALCOHOLIC STEATOHEPATITIS (NASH) ADDRESSING A GROWING SILENT EPIDEMIC
NON-ALCOHOLIC FATTY LIVER DISEASE () & NON-ALCOHOLIC STEATOHEPATITIS () ADDRESSING A GROWING SILENT EPIDEMIC PREVALENCE OF / USA Prevalence in Middle Age Patients San Antonio, Texas (Williams et al., Gastroenterology
More informationNAFLD fibrosis score: A prognostic predictor for mortality and liver complications among NAFLD patients
Online Submissions: http://www.wjgnet.com/esps/ wjg@wjgnet.com doi:10.3748/wjg.v19.i8.1219 World J Gastroenterol 2013 February 28; 19(8): 1219-1229 ISSN 1007-9327 (print) ISSN 2219-2840 (online) 2013 Baishideng.
More information대사증후군과알라닌아미노전이효소와의관련성 : 국민건강영양조사제 3 기 (2005 년 )
원저 대사증후군과알라닌아미노전이효소와의관련성 : 국민건강영양조사제 3 기 (2005 년 ) 한미아류소연박종강명근김기순 조선대학교의과대학예방의학교실 조선대학교내성세포연구센터 서론 alcoholic steatohepatitis NASH) 2 2 [1] 2001 NCEP-ATP III Panel [2] (nonalcoholic fatty liver disease
More informationNON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD) NON-ALCOHOLIC STEATOHEPATITIS (NASH) ADDRESSING A GROWING SILENT EPIDEMIC
NON-ALCOHOLIC FATTY LIVER DISEASE () & NON-ALCOHOLIC STEATOHEPATITIS () ADDRESSING A GROWING SILENT EPIDEMIC PREVALENCE OF / USA Prevalence in Middle Age Patients San Antonio, Texas (Williams et al., Gastroenterology
More informationRelationship between Serum Iron Indices and Hepatic Iron Quantitation in Patients with Fatty Liver Disease
International Journal of Business, Humanities and Technology Vol. 2 No. 5; August 2012 Relationship between Serum Iron Indices and Hepatic Iron Quantitation in Patients with Fatty Liver Disease Dr. Mariana
More informationDevelopment and validation of a simple index system to predict nonalcoholic fatty liver disease
The Korean Journal of Hepatology 2011;17:19-26 DOI: 10.3350/kjhep.2011.17.1.19 Original Article Development and validation of a simple index system to predict nonalcoholic fatty liver disease Young Jin
More informationThe histological course of nonalcoholic fatty liver disease: a longitudinal study of 103 patients with sequential liver biopsies *
Journal of Hepatology 42 (2005) 132 138 www.elsevier.com/locate/jhep The histological course of nonalcoholic fatty liver disease: a longitudinal study of 103 patients with sequential liver biopsies * Leon
More informationNAFLD/NASH. Definitions. Pathology NASH. Vicki Shah PA-C, MMS Rush University Hepatology
NAFLD/NASH Vicki Shah PA-C, MMS Rush University Hepatology Definitions NAFLD Evidence of hepatic steatosis by histology (5%) or imaging No causes for secondary fat accumulation EtOH, Drugs, hereditary
More informationPrevalence of non-alcoholic fatty liver disease in type 2 diabetes mellitus patients in a tertiary care hospital of Bihar
Original Research Article Prevalence of non-alcoholic fatty liver disease in type 2 diabetes mellitus patients in a tertiary care hospital of Bihar Naresh Kumar 1, Jyoti Kumar Dinkar 2*, Chandrakishore
More informationCLINICAL AND HISTOLOGICAL FEATURES OF NON-ALCOHOLIC STEATOHEPATITIS IN IRANIAN PATIENTS
CLINICAL AND HISTOLOGICAL FEATURES OF NON-ALCOHOLIC STEATOHEPATITIS IN IRANIAN PATIENTS N. Ebrahimi Daryani, Sh. Mirmomen, H. Bahrami, B. Haghpanah and A. Nayerhabibi Department of Gastroenterology, Imam
More informationParis Hepatology Conference PROGNOSIS OF NASH
Paris Hepatology Conference PROGNOSIS OF NASH Palais des Congrès Monday 15th January 2018 14:45-15:00 PHC 2018 - www.aphc.info Driven to care Disclosures Advisory committees Speaking and teaching Research
More informationPREVALENCE OF NAFLD & NASH
- - PREVALENCE OF & USA Prevalence in Middle Age Patients San Antonio, Texas (Williams et al., Gastroenterology 2011; 140:124-31) Dallas Heart Study Prevalence Numbers (Browning et al., Hepatology 2004;40:1387-95)
More informationWORLDWIDE EPIDEMIOLOGY OF NASH
WORLDWIDE EPIDEMIOLOGY OF NASH Stefano Bellentani, M.D., Ph.D. Chief of Gastroenterology and Hepatology Service Clinica Santa Chiara Locarno Switzerland & Fondazione Italiana Fegato (FIF), Bassovizza (Trieste),
More information«STEATOSI EPATICA ED EPATOPATIE METABOLICHE» Ester Vanni Division of Gastroenterology University of Turin
«STEATOSI EPATICA ED EPATOPATIE METABOLICHE» Ester Vanni Division of Gastroenterology University of Turin OUTLINE NAFLD overview NAFLD and menarche NAFLD and pregnancy NAFLD and menopause Other metabolic
More informationEffect of lifetime alcohol consumption on the histological severity of non-alcoholic fatty liver disease
Liver International ISSN 1478-3223 METABOLIC AND STEATOHEPATITIS Effect of lifetime alcohol consumption on the histological severity of non-alcoholic fatty liver disease Hellan K. Kwon 1, Joel K. Greenson
More informationNonalcoholic Fatty Liver Disease in Children: Typical and Atypical
Nonalcoholic Fatty Liver Disease in Children: Typical and Atypical Disclosure Naim Alkhouri, MD discloses the following relationships with commercial companies: Membership in the Speakers Bureau for Alexion
More informationFATTY LIVER DISEASE (NAFLD) (NASH) A GROWING
NON ALCOHOLIC FATTY LIVER DISEASE () & NON ALCOHOLIC S T E ATO H E PAT I T I S () ADDRESSING A GROWING SILENT EPIDEMIC Prevalence of & USA Prevalence in Middle Age Patients San Antonio, Texas (Williams
More informationNon-Alcoholic Fatty Liver Disease
Non-Alcoholic Fatty Liver Disease None Disclosures Arslan Kahloon M.D Chief, Division of Gastroenterology and Hepatology University of Tennessee College of Medicine Chattanooga Objectives Understand the
More informationThe future s bright, the future s orange. the challenges of liver disease now and in the next 50 years
The future s bright, the future s orange. the challenges of liver disease now and in the next 50 years Peter Collins Consultant Hepatologist Bristol Royal Infirmary the challenges of liver disease now
More informationNon-Alcoholic Fatty Liver Disease (NAFLD)
HEPATO-PANCREATO-BILIARY STOMACH CANCER PROGRAM Non-Alcoholic Fatty Liver Disease (NAFLD) Steatosis and Non-Alcoholic Steatohepatitis (NASH) Management Recommendations UCSF Fresno Department of Surgery
More informationBasic patterns of liver damage what information can a liver biopsy provide and what clinical information does the pathologist need?
Basic patterns of liver damage what information can a liver biopsy provide and what clinical information does the pathologist need? Rob Goldin r.goldin@imperial.ac.uk @robdgol FATTY LIVER DISEASE Brunt
More informationKeywords: NASH, insulin resistance, metformin, histopathology. William W. Shields, K.E. Thompson, G.A. Grice, S.A. Harrison and W.J.
Therapeutic Advances in Gastroenterology Original Research The effect of metformin and standard therapy versus standard therapy alone in nondiabetic patients with insulin resistance and nonalcoholic steatohepatitis
More informationABNORMAL LIVER FUNCTION TESTS. Dr Uthayanan Chelvaratnam Hepatology Consultant North Bristol NHS Trust
ABNORMAL LIVER FUNCTION TESTS Dr Uthayanan Chelvaratnam Hepatology Consultant North Bristol NHS Trust INTRODUCTION Liver function tests Cases Non invasive fibrosis measurement Questions UK MORTALITY RATE
More informationPREVALENCE OF NON-ALCOHOLIC FATTY LIVER IN A HYPERCHOLESTEROLEMIC POPULATION OF NORTHWESTERN PENINSULAR MALAYSIA
PREVALENCE OF NON-ALCOHOLIC FATTY LIVER IN A HYPERCHOLESTEROLEMIC POPULATION OF NORTHWESTERN PENINSULAR MALAYSIA Enrico Magosso 1, Mukhtar Alam Ansari 2, Yogheswaran Gopalan 1, Mohamed Rizal Abu Bakar
More informationEVALUATION OF ABNORMAL LIVER TESTS
EVALUATION OF ABNORMAL LIVER TESTS MIA MANABAT DO PGY6 MOA 119 TH ANNUAL SPRING SCIENTIFIC CONVENTION MAY 19, 2018 EVALUATION OF ABNORMAL LIVER TESTS Review of liver enzymes vs liver function tests Clinical
More informationEFFECT OF ORAL SUPPLEMENTATION OF WHEY PROTEIN ISOLATE ON NON-ALCOHOLIC STEATOHEPATITIS PATIENTS
42 EFFECT OF ORAL SUPPLEMENTATION OF WHEY PROTEIN ISOLATE ON NON-ALCOHOLIC STEATOHEPATITIS PATIENTS Prasong Tienboon MD, PhD. 1, Taned Chitapanarux MD. 2, Suwalee Pojchamarnwiputh MD. 3, Donrawee Leelarungrayub
More informationHepatology for the Nonhepatologist
Hepatology for the Nonhepatologist Kenneth E. Sherman, MD, PhD Gould Professor of Medicine Director, Division of Digestive Diseases University of Cincinnati College of Medicine Cincinnati, Ohio Learning
More informationFrequency and Outcomes of Liver Transplantation for Nonalcoholic Steatohepatitis in the United States
GASTROENTEROLOGY 2011;141:1249 1253 Frequency and Outcomes of Liver Transplantation for Nonalcoholic Steatohepatitis in the United States MICHAEL R. CHARLTON,* JUSTIN M. BURNS, RACHEL A. PEDERSEN, KYMBERLY
More informationThere is extensive literature addressing both the histopathologic
Approach to the Liver Biopsy in the Patient With Chronic Low-Level Aminotransferase Elevations Pathologists sometimes encounter a liver biopsy from an asymptomatic patient with unexplained low-level parenchymal
More informationWhy to biopsy? Indications for liver biopsy in common medical liver diseases- how are they changing?
Why to biopsy? Indications for liver biopsy in common medical liver diseases- how are they changing? Stephen D Ryder Nottingham University Hospitals NHS Trust and Biomedical research Unit What are we currently
More informationAutoimmune Hepatitis Events Easl
Autoimmune Hepatitis Events Easl 1 / 6 2 / 6 3 / 6 Autoimmune Hepatitis Events Easl INTRODUCTION. Autoimmune hepatitis is a chronic, inflammatory disease of the liver that is characterized by circulating
More informationImproving Access to Quality Medical Care Webinar Series
Improving Access to Quality Medical Care Webinar Series Presented by The Arizona Telemedicine Program and the Southwest Telehealth Resource Center 2015 UA Board of Regents Welcome AZ, UT, CO, NM & NV FLEX
More informationNew insights into fatty liver disease. Rob Goldin Centre for Pathology, Imperial College
New insights into fatty liver disease Rob Goldin Centre for Pathology, Imperial College r.goldin@imperial.ac.uk Prevalence of NASH Global prevalence of NAFLD is 25% with highest prevalence in the Middle
More informationUpdate on Nonalcoholic Fatty Liver Disease. Kathleen E Corey, MD, MPH, MMSc Director, Mass General Fatty Liver Clinic
Update on Nonalcoholic Fatty Liver Disease Kathleen E Corey, MD, MPH, MMSc Director, Mass General Fatty Liver Clinic Outline Defining the phenotypes of nonalcoholic fatty liver disease NAFLD Diagnostics
More informationIs increased red cell distribution width an indicating marker of nonalcoholic steatohepatitis and fibrotic stage?
Online Submissions: http://www.wjgnet.com/esps/ bpgoffice@wjgnet.com doi:10.3748/wjg.v19.i42.7412 World J Gastroenterol 2013 November 14; 19(42): 7412-7418 ISSN 1007-9327 (print) ISSN 2219-2840 (online)
More informationUsefulness of Magnetic Resonance Imaging for the Diagnosis of Hemochromatosis with Severe Hepatic Steatosis in Nonalcoholic Fatty Liver Disease
CASE REPORT Usefulness of Magnetic Resonance Imaging for the Diagnosis of Hemochromatosis with Severe Hepatic Steatosis in Nonalcoholic Fatty Liver Disease Yuichi Nozaki 1,NorikoSato 2, Tsuyoshi Tajima
More informationNonalcoholic Steatohepatitis with Improved Hepatic Fibrosis after Weight Reduction
CASE REPORT Nonalcoholic Steatohepatitis with Improved Hepatic Fibrosis after Weight Reduction Keita FUJIKAWA, Kazuyuki OHATA, Takuya HONDA, Seiji MIYAZOE, Tatsuki ICHIKAWA, Hiroki ISHIKAWA, Keisuke HAMASAKI,
More informationM30 Apoptosense ELISA. A biomarker assay for detection and screening of NASH
M30 Apoptosense ELISA A biomarker assay for detection and screening of NASH NASH A Global Disease In the Western countries, Non-Alcoholic Fatty Liver Disease (NAFLD) is the most common liver disease, strongly
More informationAlpha fetoprotein levels and its relationship with histopathological findings in patients with non-alcoholic fatty liver disease
European Review for Medical and Pharmacological Sciences Alpha fetoprotein levels and its relationship with histopathological findings in patients with non-alcoholic fatty liver disease M. KARA 1, H. GENC
More informationA Rational Evidence-based Approach to Abnormal Liver Tests
A Rational Evidence-based Approach to Abnormal Liver Tests Jane D. Ricaforte-Campos, MD FPCP, FPSG, FPSDE 2013 HSP Post-graduate Course Radisson Blu Hotel, Cebu City misnomer Liver Function Tests Does
More informationFREQUENCY OF NON ALCOHOLIC FATTY LIVER DISEASE (NAFLD) AND ITS BIOCHEMICAL DERANGEMENTS IN TYPE II DIABETIC PATIENTS
FREQUENCY OF NON ALCOHOLIC FATTY LIVER DISEASE (NAFLD) AND ITS BIOCHEMICAL DERANGEMENTS IN TYPE II DIABETIC PATIENTS DR. ABDUL JABBAR, MBBS DR. ABDUL BASIT, MBBS DR. HAFIZ MUHAMMAD HANNAN AKBAR, MBBS ABSTRACT
More informationMeta-Analysis of Randomized Controlled Trials of Pharmacologic Agents in Non-alcoholic Steatohepatitis
538 Said A, et al., 2017; 16 (4): 538-547 ORIGINAL ARTICLE July-August, Vol. 16 No. 4, 2017: 538-547 The Official Journal of the Mexican Association of Hepatology, the Latin-American Association for Study
More informationDesign and Validation of a Histological Scoring System for Nonalcoholic Fatty Liver Disease
Design and Validation of a Histological Scoring System for Nonalcoholic Fatty Liver Disease David E. Kleiner, 1 Elizabeth M. Brunt, 2 Mark Van Natta, 3 Cynthia Behling, 4 Melissa J. Contos, 5 Oscar W.
More informationAspartate aminotransferase-to-platelet ratio index in children with cholestatic liver diseases to assess liver fibrosis
The Turkish Journal of Pediatrics 2015; 57: 492-497 Original Aspartate aminotransferase-to-platelet ratio index in children with cholestatic liver diseases to assess liver fibrosis Aysel Ünlüsoy-Aksu 1,
More informationIS THERE A DIFFERENCE IN LIVER CANCER RATES IN PATIENTS WHO RECEIVE TREATMENT FOR HEPATITIS?
IS THERE A DIFFERENCE IN LIVER CANCER RATES IN PATIENTS WHO RECEIVE TREATMENT FOR HEPATITIS? Dr. Sammy Saab David Geffen School of Medicine, Los Angeles, USA April 2018 DISCLAIMER Please note: The views
More informationNon-Alcoholic Fatty Liver Disease An Update
Non-Alcoholic Fatty Liver Disease An Update Stefan Hübscher, School of Cancer Sciences, University of Birmingham Dept of Cellular Pathology, Queen Elizabeth Hospital, Birmingham First described in 1980
More informationPrevalence of non-alcoholic fatty liver disease (NAFLD) in type 2 diabetic patients in correlation with coronary artery disease
Original Research Article Prevalence of non-alcoholic fatty liver disease (NAFLD) in type 2 diabetic patients in correlation with coronary artery disease Ramulu Pulimaddi 1*, Amruth Rao Parveda 2, Dhanunjaya
More informationNonalcoholic Steatohepatitis National Digestive Diseases Information Clearinghouse
Nonalcoholic Steatohepatitis National Digestive Diseases Information Clearinghouse National Institute of Diabetes and Digestive and Kidney Diseases NATIONAL INSTITUTES OF HEALTH Nonalcoholic steatohepatitis
More informationThe Efficacy of Corticosteroid Therapy in a Patient with Nonalcoholic Steatohepatitis Overlapping Autoimmune Hepatitis: A Case Report
doi: 10.2169/internalmedicine.8887-17 Intern Med Advance Publication http://internmed.jp CASE REPORT The Efficacy of Corticosteroid Therapy in a Patient with Nonalcoholic Steatohepatitis Overlapping Autoimmune
More informationThe classical metabolic work-up, approved by the Ethics Committee of the Antwerp
SUPPLEMENTARY MATERIALS METHODS Metabolic work-up The classical metabolic work-up, approved by the Ethics Committee of the Antwerp University Hospital and requiring written informed consent, included a
More informationThe New England Journal of Medicine
The New England Journal of Medicine Primary Care EVALUATION OF ABNORMAL LIVER-ENZYME RESULTS IN ASYMPTOMATIC PATIENTS DANIEL S. PRATT, M.D., AND MARSHALL M. KAPLAN, M.D. NOW that routine laboratory testing
More informationAn association between coffee consumption and
Association of Coffee and Caffeine Consumption With Fatty Liver Disease, Nonalcoholic Steatohepatitis, and Degree of Hepatic Fibrosis Jeffrey W. Molloy, 1 Christopher J. Calcagno, 2 Christopher D. Williams,
More informationPITFALLS IN THE DIAGNOSIS OF MEDICAL LIVER DISEASE WITH TWO CONCURRENT ETIOLOGIES I HAVE NOTHING TO DISCLOSE CURRENT ISSUES IN ANATOMIC PATHOLOGY 2017
CURRENT ISSUES IN ANATOMIC PATHOLOGY 2017 I HAVE NOTHING TO DISCLOSE Linda Ferrell PITFALLS IN THE DIAGNOSIS OF MEDICAL LIVER DISEASE WITH TWO CONCURRENT ETIOLOGIES Linda Ferrell, MD, UCSF THE PROBLEM
More informationScreening cardiac patients for advanced liver disease
HKASLD 30 th ASM and International Symposium on Hepatology 2017 Screening cardiac patients for advanced liver disease 5 Nov 2017 Dr. Lau Yue Leung Joulen Pamela Youde Nethersole Eastern Hospital NAFLD
More informationNormal ALT for men 30 IU/L 36% US males abnormal. Abnl ALT. Assess alcohol use/meds. Recheck in 6-8 weeks. still pos
Fatty liver disease Its not just for big boys anymore Ken Flora, MD, FAASLD, FACG, AGAF No disclosures Common situation Normal ALT for men 30 IU/L 36% US males abnormal Normal ALT for women 20 IU/L 28%
More informationCorrelation between bright echogenic liver, elevated liver enzymes and liver histology.
Original Article Correlation between bright echogenic liver, elevated liver enzymes and liver histology. Dr. Iqbal Murshed Kabir, Dr. Mahbub Alam, Dr. Mohammad Mahmuduzzaman, Dr. Abdullah Al Mamoon, Dr.
More informationSimple non-invasive fibrosis scoring systems can reliably exclude advanced fibrosis in patients with non-alcoholic fatty liver disease
1 Liver Unit, Newcastle Upon Tyne Hospitals NHS Trust, Freeman Hospital, Newcastle upon Tyne, UK 2 Institute of Cellular Medicine, Faculty of Medical Sciences, Newcastle University, Newcastle Upon Tyne,
More informationNONALCOHOLIC FATTY LIVER DISEASE
NONALCOHOLIC FATTY LIVER DISEASE Kiran Bambha, MD, MSc Hepatology and Liver Transplantation University of Colorado Denver April 13, 2012 Non-Alcoholic Fatty Liver Disease (NAFLD) Terminology Pathogenesis
More informationTransient elastography in chronic liver diseases of other etiologies
4 Post Meeting A.I.S.F. Unmet Clinical Needs in Hepatology: New and upcoming diagnostic tools" Transient elastography in chronic liver diseases of other etiologies Dr. Vincenza Calvaruso Gastroenterologia
More informationAt Least 1 in 5 Patients in Your Practice Have Fatty Liver
At Least 1 in 5 Patients in Your Practice Have Fatty Liver What Can You Tell Your Patients Magnus McLeod MD FRCPC Assistant Professor Dalhousie University 30-NOV-2017 NAFLD Non-Alcoholic Fatty Liver Disease
More informationNonalcoholic fatty liver disease: A manifestation of the metabolic syndrome
REVIEW CME CREDIT CHIN HEE KIM, MD Center for Liver Diseases Inova Fairfax Hospital, Falls Church, VA ZOBAIR M. YOUNOSSI, MD, MPH * Center for Liver Diseases Inova Fairfax Hospital, Falls Church, VA; Executive
More informationAre we adequately screening at-risk patients for hepatocellular carcinoma in the outpatient setting?
Rajani Sharma, PGY1 Geriatrics CRC Project, 12/19/13 Are we adequately screening at-risk patients for hepatocellular carcinoma in the outpatient setting? A. Study Purpose and Rationale Hepatocellular carcinoma
More information